CURRICULUM VITAE. Rafael A. Rivas-Vazquez, Psy.D.

Transcription

1 Office Address Home Address NeuroScience Consultants 8940 North Kendall Drive Suite 802-E Miami, Florida Woodcrest Road Key Biscayne, Florida Date of Birth January 25, 1962 Place of Birth Miami, Florida Education 1983 Bachelor s of Science in Psychology Georgetown University 1990 Doctorate in Clinical Psychology Nova Southeastern University 2001 Master s of Science in Clinical Psychopharmacology Nova Southeastern University Pre-doctoral and Post-doctoral Training Harvard Medical School/Massachusetts General Hospital University of Miami School of Medicine Licensure 1991 Florida Board of Psychology, License #PY Board Certification 1997 American Board of Professional Psychology Diplomate in Clinical Psychology, Certificate #5039 Board Appointments 2002 Board of Psychology, Member Department of Health, State of Florida Board of Psychology, Chairperson Department of Health, State of Florida 2010 Board of Psychology, Chairperson Department of Health, State of Florida

2 Page 2 Academic Appointments Clinical Fellow in the Department of Psychiatry Harvard Medical School Instructor in the Department of Psychiatry Harvard Medical School Voluntary Assistant Professor in the Department of Neurology University of Miami Medical School 2003 Adjunct Associate Professor in the Department of Psychology University of Miami Staff Appointments Clinical Fellow in Psychology Massachusetts General Hospital, Boston, MA Staff Psychologist New England Memorial Hospital, Stoneham, MA Consulting Staff Charter Hospital, Miami, FL 1992 Staff Psychologist Citrus Health Network, Hialeah, FL 1993 Active Staff Baptist Health Systems, Miami, FL Professional Experience Coordinator of Inpatient Training for Pre-doctoral Internship Massachusetts General Hospital, Boston, MA Staff Psychologist Massachusetts General Hospital, Boston, MA Director, Mobile Crisis Services for Hurricane Andrew Relief Effort Northwest Dade Mental Health Center, Hialeah, FL 1994 Director, Assessment and Emergency Service Citrus Health Network, Hialeah, FL Clinical Director AuroraCare Behavioral Managed Care Company, Miami, FL 1996 Neuropsychologist NeuroScience Consultants, Miami, FL 1998 Co-director and Investigator, Neuroscience Division Miami Research Associates, Miami, FL Clinical Director Baptist Memory Disorders Center, Miami, FL

3 Page 3 Committee Assignments South Florida Interprofessional Council Representative Dade County Psychological Association Peer Review/Medical Records Committee Charter Hospital of Miami Peer Review and Credentialing Committee Northwest Dade Mental Health Center Psychopharmacology Committee, Chairperson Dade County Psychological Association 1995 Performance Improvement Committee Citrus Health Network Quality Assurance/Utilization Management PsychStar Behavioral Managed Care Company Medical Advisory Board Alzheimer s Association of Greater Miami Quality Improvement Committee, Chairperson Citrus Health Network 2002 Psychology Steering Committee Baptist Health Systems Continuing Education Committee Board of Psychology, State of Florida 2005 Probable Cause Panel, Chairperson Board of Psychology, State of Florida Memberships in Professional Associations 1986 Florida Psychological Association 1986 American Psychological Association 1993 International Neuropsychological Society 1995 Hispanic Neuropsychological Society Original Reports 1) Rivas-Vazquez, R., & Blais, M. (1997). Selective serotonin reuptake inhibitors and atypical antidepressants: A review and update for psychologists. Professional Psychology: Research and Practice, 28, ) Carrazana, E., DeToledo, J., Tatum, W., Wheeler, S., & Rivas-Vazquez, R. (1999). Epilepsy and religious experiences: Voodoo possession. Epilepsia, 40, ) Rivas-Vazquez, R., Johnson S.L., Blais, M., & Rey, G. (1999). Selective serotonin reuptake inhibitor discontinuation syndrome: Understanding, recognition and management for psychologists. Professional Psychology: Research and Practice, 30, ) Rey, G.J., Feldman, E., Rivas-Vazquez, R., Levin, B.E., & Benton, A.L. (1999). Neuropsychological test development and normative data on Hispanics. Archives of Clinical Neuropsychology, 14,

4 Page 4 5) Rivas-Vazquez, R., Blais, M.A., Rey, G.J., & Rivas-Vazquez, A. (2000). Atypical antipsychotics: Pharmacologic profiles and psychologic implications. Professional Psychology: Research and Practice, 31, ) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., Blais, M.A., & Racher, D.A. (2000). Alzheimer s disease: Pharmacologic treatment and management. The Clinical Neuropsychologist, 14, ) Rivas-Vazquez, R., Rivas-Vazquez A, Rey, G.J., & Blais, M.A. (2000). Sexual dysfunction associated with antidepressant treatment. Professional Psychology: Research and Practice, 31, ) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Wheeler, S.D. (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: Three cases presenting to a neurologic practice. The Neurologist, 6, ) Rivas-Vazquez, R. (2001). Antidepressants as first-line agents in the current pharmacotherapy of anxiety disorders. Professional Psychology: Research and Practice, 32, ) Carrazana, E., Rey, G., Rivas-Vazquez, R., & Tatum, W. (2001). Ictal alien hand syndrome. Epilepsy and Behavior, 2, ) Rivas-Vazquez, R., Blais, M., Rey, G., & Rivas-Vazquez, A. (2001). A brief reminder about documenting the psychological consultation. Professional Psychology: Research and Practice, 32, ) Rivas-Vazquez, R. (2001). Reboxetine: Refocusing on the role of norepinephrine in the treatment of depression. Professional Psychology: Research and Practice, 32, ) Rey, G.J., Feldman, E., Hernandez, D., Levin, B.E., Rivas-Vazquez, R., LeBlanc, W.G., & Benton, A.L. (2001). Application of the Multilingual Aphasia Examination - Spanish in the evaluation of Hispanic patients post-traumatic brain injury. The Clinical Neuropsychologist, 15, ) Rivas-Vazquez, R. (2001). St. John s wort (Hypericum perforatum): Practical considerations based on the evidence. Professional Psychology: Research and Practice, 32, ) Carrazana, E.J., Rivas-Vazquez, R., Rey J, & Rey, G.J. (2001). SSRI discontinuation syndrome exacerbated by buspirone (letter). American Journal of Psychiatry, 158, ) Rivas-Vazquez, R. (2001). Cholinesterase inhibitors: Current pharmacological treatments for Alzheimer's disease. Professional Psychology: Research and Practice, 32, ) Blais, M., Rivas-Vazquez, R., Rey, G.J., Racher, D.A., & Carrazana, E.J. (2001). Treatment and management of Alzheimer's disease. Clinical Geriatrics, 9, ) Rivas-Vazquez, R. (2001). Understanding drug interactions. Professional Psychology: Research and Practice, 32, ) Rivas-Vazquez, R., Rivas-Vazquez, A., Blais, M., Rey, G.J., Rivas-Vasquez, F., Jacobo, M., & Carrazana, E.J. (2001). Development of a Spanish version of the Schwartz Outcome Scale - 10: A brief mental health outcome measure. Journal of Personality Assessment, 77,

5 Page 5 20) Rivas-Vazquez, R. (2001). Ziprasidone: Pharmacological and clinical profile of the newest atypical antipsychotic. Professional Psychology: Research and Practice, 32, ) Rivas-Vazquez, R., & Blais, M. (2002). Pharmacologic treatment of personality disorders. Professional Psychology: Research and Practice, 33, ) Rivas-Vazquez, R., Johnson, S.L., Rey, G.J., & Blais, M. (2002). Current treatments for bipolar disorder: A review and update for psychologists. Professional Psychology: Research and Practice, 33, ) Rivas-Vazquez, R., & Rey, J. (2002). Weight gain and metabolic disturbances associated with the atypical antipsychotics. Professional Psychology: Research and Practice, 33, ) Rivas-Vazquez, R., & Delgado, L. (2002). Clinical and toxic effects of MDMA ( Ecstasy ). Professional Psychology: Research and Practice, 33, ) Rivas-Vazquez, R., & Mendez, C.I. (2002). Overview of the drug approval process. Professional Psychology: Research and Practice, 33, ) Blais, M.A., Matthews, J., Lipkis-Orlando, R., O Keefe, S.M., Jacobo, M., Rivas- Vazquez, R.A, & Summergrad, P. (2002). Development and application of a multifaceted tool for evaluating inpatient psychiatric care. Administration and Policy in Mental Health, 30, ) Rivas-Vazquez, R.A. (2003). Aripiprazole: A novel antipsychotic with dopamine stabilizing properties. Professional Psychology: Research and Practice, 34, ) Rivas-Vazquez, R.A., & Perel, J.M. (2003). The role of stereochemistry and chiral pharmacology in psychotropic drug development. Professional Psychology: Research and Practice, 34, ) Rivas-Vazquez, R.A. (2003). Benzodiazepines in contemporary clinical practice. Professional Psychology: Research and Practice, 34, ) Feldman, L.B., & Rivas-Vazquez, R.A. (2003). Assessment and treatment of social anxiety disorder. Professional Psychology: Research and Practice, 34, ) Rivas-Vazquez, R.A, & Resnick, M. (2003). The emerging role of glutamate in the pathophysiology and treatment of psychiatric disorders. Professional Psychology: Research and Practice, 34, ) Rivas-Vazquez, R.A, Rice, J., & Kalman, D. (2003). Pharmacotherapy of obesity and eating disorders. Professional Psychology: Research and Practice, 34, ) Rivas-Vazquez, R.A. (2003). Atomoxetine: A selective norepinephrine reuptake inhibitor for the treatment of Attention-Deficit/Hyperactivity Disorder. Professional Psychology: Research and Practice, 34, ) Rivas-Vazquez, R.A, Mendez, C., Rey, G.J., & Carrazana, E.J. (2004). Mild cognitive impairment: New neuropsychological and pharmacological target. Archives of Clinical Neuropsychology, 19, ) Rivas-Vazquez, R.A, Saffa-Biller, D., Ruiz, I., Blais, M.A., & Rivas-Vazquez, A. (2004). Current issues in anxiety and depression: Comorbid, mixed and subthreshold disorders. Professional Psychology: Research and Practice, 35,

6 Page 6 36) Rivas-Vazquez, R.A., Sarria, M., Rey, G., Rivas-Vazquez, A., Rodriguez, J. & Jardon, M. (2009). A relationship-based care model for jail diversion. Psychiatric Services, 60, ) Rivas-Vazquez, R.A., Bello, I., Sarria, M., Fernandez, N., & Rey, G.J. (2011). Prevalence of Metabolic Syndrome in a Predominantly Cuban, Psychiatrically Ill and Homeless Population. Primary Care Companion for CNS Disorders, 13(3), e1 e5. 38) Rey, G.J., Rivas-Vazquez, R., Garaycoa, G., Mendez, C., Bello, I., & Carrazana, E.J. (in press). A prospective study monitoring AD patients during a switch from donepezil to rivastigmine. The Neurologist. 39) Blais, M.A., Blagys, M.D., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R., Orlandini, E., & Bello, I. (in press). Development and initial validation of an ultrabrief measure of psychiatric symptom distress. Journal of Personality Assessment. 40) Rey, G.J., Schatz, N., Bauerlain, E.J., Bowen, B., Rivas-Vazquez, R., & Carrazana, E.J. (under review). Transient Balint's syndrome following heart transplantation. Neuroophthalmology. Book Chapters 1) Blais, M., Smallwood, P., Groves, J., & Rivas-Vazquez R. Personality and Personality Disorders. In T. Sterns, J. Rosenbaum, M. Fava, J. Biedermen & S. Rauch (Ed.) Handbook of Comprehensive Clinical Psychiatry (2008, pp ). Abstracts 1) Rivas-Vazquez, A., & Rivas-Vazquez, R. (1986, May). Family restructuring: An alternative to teen suicide. Presented at the American Association of Suicidology Conference, Atlanta, Georgia. 2) Rey, G.J., Feldman, E., Rivas-Vazquez, R., & Benton, A.L. (1994, August). Current trends and future of neuropsychological research with Hispanics. Presented at the annual meeting of the American Psychological Association, Los Angeles, California. 3) Rey, G.J., Levin, B.E., Brown, M.C., Feldman, E., Rivas-Vazquez, R., Arias, M., & Benton, A.L. (1995). Application of the Benton tests to Hispanic adults: A preliminary analysis. Journal of the International Neuropsychological Society, 1. 4) Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Epilepsy and religious experiences: Voodoo possession. Presented at the annual meeting of the American Epilepsy Society, San Diego, California. 5) Carrazana, E., DeToledo, J., Tatum, W., Rivas-Vazquez, R., Rey, G., Wheeler, S., & Ramirez-Mejia, C. (1998, December). Erroneous attribution of epileptic seizures to voodoo spirit possession. Presented at the troisieme Congres de Neurologie Tropicale, Martinique. 6) Rivas-Vazquez, R., Carrazana, E.J., Rey, G.J., & Mendoza, R. (1999, January). Clinical and psychosocial characteristics of Caribbean and Anglo-Saxon dementia referrals in South Florida. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana.

7 Page 7 7) Rey, G.J., Rivas-Vazquez, R., Feldman, E., & Carrazana, E.J. (1999, January). The evaluation of executive functions in Hispanics. Presented at the tenth annual meeting of the American Neuropsychiatric Association, New Orleans, Louisiana. 8) Carrazana, E.J., Wheeler, S., Aptman, M., Zwibel, H., Kobetz, S., Racher, D., Grant, T., Faradji, V., Ramirez-Mejia, C., Rivas-Vazquez, R., & Rey, G.J. (1999, December). Second generation anticonvulsants utilization in clinical neurology (abstract #10022). Presented at the annual meeting of the American Epilepsy Society, Orlando, Florida. 9) Rivas-Vazquez, R., Rey, G.J., Blais, M.A., Carrazana, E.J., & Schwartz, H. (2000, June). Development and validation of the Spanish version of the Schwartz Outcome Scale Presented at the 40 th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida. 10) Rey, G.J., Rivas-Vazquez, R., Carrazana, E.J., Mendoza, R., Garaycoa, G., & Schwartz, H. (2000, June). Cross-cultural comparisons of dementia referrals in South Florida: Clinical and psychosocial factors. Presented at the 40th annual New Clinical Drug Evaluation Unit meeting, Boca Raton, Florida. 11) Carrazana, E.J., Espinosa, I., Wheeler, S., Espinosa, J., Rey, G.J., Rivas-Vazquez, R., & Ramirez-Mejia, C. (2000, December). Is folic acid for reduction of anticonvulsants teratogenic risk part of the standard neuropsychiatric clinical practice? Results of a survey. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California. 12) Rey, G.J., Carrazana, E.J., Garaycoa, G., Rivas-Vazquez, R., Espinosa, I., & Ramirez- Mejia, C. (2000, December). Affective disorders in juvenile myoclonic epilepsy: A prospective study. Presented at the annual meeting of the American Epilepsy Society, Los Angeles, California. 13) Johnson, S.L., Rugerro, C., Winters, R., Gotlib, I.H., Ahmed, Z., & Rivas-Vazquez, R. (2001, July). The behavioral activation system and mania: Cognitive-behavioral implications. Presented at the annual meeting of the World Congress of Behavioral and Cognitive Therapies, Vancouver, British Columbia. 14) Blagys, M.D., Blais, M.A., Lechner, E., Rivas-Vazquez, R., Martinez-Arrue, R., Orlandini, E., & Bello, I. (2002, March). Initial development of an ultra-brief measure of psychiatric symptoms distress: The AT-25. Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas 15) Miller, D., Gonzalez, E., Rivas-Vazquez, R., & Blais, M.A. (2002, March). The Word Association Test (WAT): A predictor of suicide? Presented at the midwinter meeting of the Society for Personality Assessment meeting, San Antonio, Texas 16) Rey, G.J., Garaycoa, G., Rivas-Vazquez, R., Bello, I., Campos, L., & Carrazana, E.J. (2002, May). Clinical and neuropsychological findings in patients with Alzheimer s disease during switch from donepezil to rivastigmine. Presented at the annual meeting of the American Geriatrics Society, Washington, D.C. 17) Rey, G.J., Rivas-Vazquez, R., Mendoza, R., Garaycoa, G., & Carrazana, E. (2005, February). A Spanish verbal learning test: normative and clinical data. Presented at the 33 rd annual International Neuropsychological Society meeting, San Louis, Missouri.

8 Page 8 18) Rey, G.J., Mendez, C., Rivas-Vazquez, R., & Bello, I. (2005, February). Neuropsychiatric symptomatology and caregiver distress in Alzheimer s Disease: A comparison of Hispanic and Anglosaxon groups. Presented at the 33 rd annual International Neuropsychological Society meeting, San Louis, Missouri. 19) Sarria, M., Rivas-Vazquez, R.A., & Martinez, H. (2008, March). Relationship-based care effects on jail diversion. Presented at the 2008 CMHS National GAINS Center Conference, Washington, D.C. Other Publications 1) Rivas-Vazquez, R. (1990). Assessing differential levels of affective expression in bilingual subjects using the Thematic Apperception Test. Unpublished doctoral dissertation. Nova Southeastern University, Florida. 2) Rivas-Vazquez, R., & Samek, W.R. (1996). Update on prescription privileges. Florida Psychologist, 47, ) Carrazana, E.J., & Rivas-Vazquez, R. (1999). Antiepileptic drugs in the management of mood disorders. Monograph supported by unrestricted grant from Parke- Davis/Warner Lambert. 4) Rivas-Vazquez, R., Johnson, S.L., Blais, M., & Rey, G. (2000). Recognizing SSRI discontinuation syndrome. Clinician s Research Digest, 18, 3. Lectures and Presentations 1) Effects of language on assessment and treatment of Hispanic patients. Presented at Massachusetts General Hospital/Chelsea Mental Health Center Teaching Rounds, May 1991, Boston, Massachusetts. 2) Introduction to DSM-IV. Presented at Northwest Dade Mental Health Center Grand Rounds, August 1994, Hialeah, Florida. 3) Clinical best practices in Medicaid managed care. Presented at Public/Private Regional Symposia: Integrating Public and Private Funding Streams and Delivery Systems in Behavioral Health Care, October 1996, Clearwater Beach, Florida. 4) An update on Medicaid managed care in Florida. Presented at Linking Forces VI: The Sixth Annual Children's Mental Health Conference, May 1997, Miami, Florida. 5) Overview of Alzheimer's disease. Presented at The Alzheimer's Association Fifth Annual Educational Forum, November 1997, Miami, Florida. 6) Alzheimer's management and treatment issues. Sponsored by the Puerto Rican Neurophysiology Society and Pfizer-Eisai Pharmaceutical Companies. May 1998, San Juan, Puerto Rico. 7) Dementia 99: An update in diagnosis, treatment and reimbursement. Sponsored by Novartis Pharmaceuticals Corporation. February 1999, Boca Raton, Florida. 8) Psychological aspects of headaches. Presented at the Baptist Hospital Symposium for migraine management May 1999, Miami, Florida. 9) Impact of psychosocial stress on diabetes control. Presented at the Diabetes 2000: Management strategies for the new millennium. Sponsored by the Diabetes Care Centers of Baptist Health Systems. July 1999, Barcelona, Spain.

9 Page 9 10) Cognitive issues associated with the use of antipsychotics in elderly patients. Presented at the Novartis Advisory Board Meeting: Psychosis in the elderly patient. February 2002, New Orleans, Louisiana. 11) Baker act: Responsibilities and risks under the law. Presented at the South Florida Hospital and Healthcare Association Meeting, November 2008, Weston, Florida. Pharmaceutical Associations Parke-Davis, Warner Lambert Pharmaceutical Speakers Bureau Janssen Pharmaceutica Speakers Bureau Novartis Pharmaceuticals Corporation National Speakers Bureau Eisai Inc., Speakers Bureau Research Experience 1) Principal Investigator, Berlex Laboratories: Multiple Sclerosis, June ) Sub-investigator, Parke-Davis: Alzheimer s Disease, April ) Sub-investigator, Protodigm, LTD: Alzheimer's Disease, May ) Sub-investigator, Bristol Myers Squibb: Generalized Anxiety Disorder, June ) Sub-investigator, Bayer Pharmaceuticals: Alzheimer's Disease, September ) Sub-investigator, Takeda: Alzheimer's Disease, March ) Sub-investigator, Bristol-Myers Squibb: Generalized Anxiety Disorder, April ) Sub-investigator, Merck & Co., Inc.: Major Depressive Disorder, April ) Principal Investigator, SmithKline Beecham: Generalized Anxiety Disorder, December ) Principal Investigator, SmithKline Beecham: Posttraumatic Stress Disorder, February ) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, February ) Sub-investigator, Medeva Development: Pediatric Attention Deficit Hyperactivity Disorder, April ) Sub-investigator, Bristol-Myers Squibb: Pediatric Generalized Anxiety Disorder, July ) Sub-investigator, Bristol-Myers Squibb: Major Depressive Disorder, July ) Sub-investigator, Neo-Therapeutics: Alzheimer's Disease, September ) Sub-investigator, SmithKline Beecham: Premenstrual Dysphoric Disorder, September ) Sub-investigator, Eisai: Dementia Associated with Cerebrovascular Disease, October ) Sub-investigator, Novartis: Mild Cognitive Impairment, December ) Sub-investigator, Tap Holdings, Inc.: Major Depressive Disorder, January ) Principal Investigator, Wyeth-Ayerst: Social Anxiety Disorder, February ) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, March ) Sub-investigator, Pharmacia-Upjohn: Major Depressive Disorder, April ) Sub-investigator, Eli Lilly: Generalized Anxiety Disorder, August 2000

10 Page 10 24) Sub-investigator, Wyeth-Ayerst: Pediatric Generalized Anxiety Disorder, August ) Sub-investigator, Wyeth-Ayerst: Adolescent Social Anxiety Disorder, August ) Sub-investigator, Pharmacia-Upjohn: Major Depressive Disorder, October ) Sub-investigator, Pfizer: Alzheimer's Disease, February ) Sub-investigator, Forest Laboratories: Generalized Anxiety Disorder, March ) Sub-investigator, Janssen: Alzheimer's Disease, March ) Sub-investigator, Forest Laboratories: Moderate to Severe Alzheimer's Disease, April ) Sub-investigator, SmithKline Beecham: Major Depressive Disorder with Anxiety, April ) Sub-investigator, Janssen: Mild Cognitive Impairment, April ) Sub-investigator, Wyeth-Ayerst: Panic Disorder, April ) Sub-investigator, Forest Laboratories: Generalized Anxiety Disorder, May ) Sub-investigator, Eli Lilly: Schizophrenia, September ) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, GlaxoSmithKline: Major Depressive Disorder, September ) Sub-investigator, Pfizer: Major Depressive Disorder with Somatic Symptoms, September ) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, December ) Sub-investigator, Novartis: Cerebrovascular Dementia, February ) Sub-investigator, Eli Lilly: Antipsychotic-induced weight gain, March ) Sub-investigator, Forest Laboratories: Mild to Moderate Alzheimer's Disease, April ) Sub-investigator, Pharmacia Upjohn: Generalized Anxiety Disorder, April ) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, July ) Principal Investigator, Wyeth-Ayerst: Major Depressive Disorder, October ) Sub-investigator, Eli Lilly: Fibromyalgia with or without depression, November ) Sub-investigator, Forest Laboratories: Major Depressive Disorder, November ) Sub-investigator, Sanofi-Synthelabo: Smoking Cessation, November ) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, December ) Sub-investigator, Johnson & Johnson: Mild Cognitive Impairment, January ) Sub-investigator, GlaxoSmithKline: Major Depressive Disorder, April ) Sub-investigator, Sanofi-Synthelabo: Alzheimer's Disease, June ) Sub-investigator, Sanofi-Synthelabo: Major Depressive Disorder, August ) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, September ) Sub-investigator, Pfizer: Fibromyalgia, October ) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder, November 2003

11 Page 11 58) Sub-investigator, Merck & Co., Inc.: Alzheimer's Disease, November ) Sub-investigator, Wyeth Research: Alzheimer's Disease, November ) Principal Investigator, Wyeth Research: Major Depressive Disorder, December ) Sub-investigator, Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, January ) Sub-investigator, Eli Lilly: Pediatric Attention Deficit Hyperactivity Disorder and Dyslexia, January ) Principal Investigator, Wyeth Research: Major Depressive Disorder, January ) Sub-investigator, Sepracor: Insomnia related to Major Depressive Disorder, March ) Sub-investigator, Cephalon: Pediatric Attention Deficit Hyperactivity Disorder, May ) Sub-investigator, GlaxoSmithKline: Parkinson's Disease, May ) Sub-investigator, Schering-Plough: Hepatitis C, May ) Sub-investigator, Sanofi-Synthelabo: Fibromyalgia, June ) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, Eli Lilly: Major Depressive Disorder, November ) Sub-investigator, Cephalon: Generalized Anxiety Disorder, November ) Sub-investigator, Pfizer: Insomnia, November ) Sub-investigator, Cephalon: Generalized Anxiety Disorder, January ) Sub-investigator, Novartis: Generalized Anxiety Disorder, March ) Sub-investigator, Sanofi-Synthelabo: Major Depressive Disorder, March ) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, March ) Sub-investigator, Cephalon: Narcolepsy in Children and Adolescents, June ) Sub-investigator, Cephalon: Obstructive Sleep Apnea in Children and Adolescents, June ) Sub-investigator, Eli Lilly: Fibromyalgia, July ) Sub-investigator, Cephalon: Excessive Sleepiness in Children and Adolescents, July ) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, July ) Sub-investigator, Shire Laboratories: Adult Attention Deficit Hyperactivity Disorder, July ) Sub-investigator, Sanofi-Synthelabo: Generalized Anxiety Disorder, December ) Sub-investigator, Pfizer/Neurocrine Biosciences: Insomnia and Major Depressive Disorder, November ) Sub-investigator, Pfizer: Generalized Anxiety Disorder, November ) Principal Investigator, Wyeth Research: Major Depressive Disorder, February, 2006

12 Page 12 89) Sub-investigator, Wyeth Research: Fibromyalgia, June ) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity Disorder, June ) Sub-investigator, Wyeth Research: Fibromyalgia (Open-label Extension), August ) Sub-investigator, New River Pharmaceuticals: Adult Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, INC Research: Mild Cognitive Impairment following Coronary Artery Bypass Graft, October ) Sub-investigator, Novartis: Major Depressive Disorder, October ) Sub-investigator, Eisai: Parkinson's Disease, November ) Sub-investigator, Wyeth Research: Alzheimer's Disease, November ) Sub-investigator, Boehringer-Ingelheim: Parkinson's Disease, December ) Sub-investigator, Shire Development Inc: Pediatric Attention Deficit Hyperactivity Disorder with Oppositionality, January ) Sub-investigator, Eli Lilly: Adult Attention Deficit Hyperactivity Disorder, January ) Sub-investigator, Shire Pharmaceutical Development Inc: Pediatric Attention Deficit Hyperactivity Disorder, January ) Sub-investigator, Eli Lilly: Chronic Lower Back Pain, January ) Principal Investigator, Wyeth Research: Major Depressive Disorder, March ) Sub-investigator, Shire Laboratories: Pediatric Attention Deficit Hyperactivity Disorder, May ) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity Disorder, May ) Sub-investigator, Eli Lilly: Pediatric Major Depressive Disorder, June ) Sub-investigator, Wyeth Research: Alzheimer's Disease, June ) Sub-investigator, Shire Laboratories: Adolescent Attention Deficit Hyperactivity Disorder, July ) Sub-investigator, Abbott Laboratories: Adult Attention Deficit Hyperactivity Disorder, July ) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, August ) Sub-investigator, Arena Pharmaceuticals, Obesity, January ) Sub-investigator, Novartis, Major Depressive Disorder, February ) Sub-investigator, Johnson and Johnson PRD, LLC: Adult Attention Deficit Hyperactivity Disorder, March ) Sub-investigator, Elan: Alzheimer's Disease, April ) Sub-investigator, Takeda: Major Depressive Disorder, April ) Sub-investigator, Pfizer Inc: Adults with Nonrestorative Sleep, April ) Sub-investigator, Sepracor: Pediatric Attention Deficit Hyperactivity Disorder with Insomnia, June ) Sub-investigator, Eli Lilly, Fibromyalgia, June ) Sub-investigator, Takeda: Generalized Anxiety Disorder, June ) Sub-investigator, Pfizer Inc: Generalized Anxiety Disorder, June ) Sub-investigator, Schering-Plough: Obesity, July 2008

13 Page ) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity Disorder, September ) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, October ) Sub-investigator, Shire Laboratories, Pediatric Attention Deficit Hyperactivity Disorder (Extension), November ) Sub-investigator, Pfizer Inc., Generalized Anxiety Disorder (Open-label Extension), November ) Sub-investigator, Pfizer Inc., Alzheimer's Disease, December ) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, December ) Sub-investigator, Johnson and Johnson PRD, LLC, Adult Attention Deficit Hyperactivity Disorder, March ) Sub-investigator, Eli Lilly, Osteoarthritis Knee Pain, March ) Sub-investigator, Neurogen Corporation, Restless Leg Syndrome, April ) Sub-investigator, Mylan Pharmaceuticals, Inc, Schizophrenia, June ) Principle Investigator, Wyeth Research, Major Depressive Disorder, June ) Sub-investigator, Shire Laboratories, Adult Attention Deficit Hyperactivity Disorder, June ) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder, July ) Principle Investigator, Wyeth Research, Major Depressive Disorder, July ) Sub-investigator, Pfizer Inc., Sleep Maintenance, July ) Sub-investigator, Eli Lilly, Pediatric Attention Deficit Hyperactivity Disorder (Openlabel Extension), September ) Sub-investigator, Cephalon, Mild to Moderate Closed Traumatic Brain Injury, October ) Sub-investigator, Eli Lilly, Obesity, October ) Sub-investigator, Bristol-Myers Squibb, Alzheimer's Disease, October ) Sub-investigator, Elan, Alzheimer's Disease (Extension), December ) Sub-investigator, Pfizer, Restless Legs Syndrome, January ) Sub-investigator, Tibotec Pharmaceuticals, Hepatitis C, January ) Sub-investigator, Cephalon, Excessive Sleepiness Associated with Shift Work, March ) Sub-investigator, Forest Laboratories, Major Depressive Disorder, March ) Sub-investigator, Otsuka, Adult Attention Deficit Hyperactivity Disorder, June ) Sub-investigator, Novartis, Major Depressive Disorder, July ) Sub-investigator, Novartis, Migraines, November ) Sub-investigator, Novartis, Pediatric Attention Deficit Hyperactivity Disorder, December ) Sub-investigator, Janssen, Alzheimer's Disease, January ) Sub-investigator, Eli Lilly, Migraines, March ) Sub-investigator, AstraZeneca, Major Depressive Disorder, May ) Sub-investigator, Abbott, Major Depressive Disorder, June 2011

14 Page ) Sub-investigator, Shire Laboratories, Adolescent Attention Deficit Hyperactivity Disorder, October ) Sub-investigator, Shionogi Inc., Pediatric Attention Deficit Hyperactivity Disorder, October ) Sub-investigator, Roche, Multiple Sclerosis, November ) Sub-investigator, Bristol-Myers Squibb, Migraines, November ) Sub-investigator, Pfizer, Sensorineural Hearing Loss, December ) Sub-investigator, Forest Laboratories, Major Depressive Disorder, December 2011 UPDATED DECEMBER 2011